Injectable versions, like semaglutide (Wegovy) and tirzepatide (Zepbound) , helped people lose 1520% of their body weight in clinical trials, transforming what doctors thought was possible
moreover, significant weight loss reduces the requirement for procedures, such as coronary artery bypass grafting, carotid endarterectomy, and percutaneous coronary intervention, as well as peripheral vascular disease, and total mortality by up to 24% [89, 90]
This anti-inflammatory effect could potentially help in managing autoimmune conditions where inflammation is a major contributor to disease progression
It is available only for laboratory research
What to discuss with your doctor: Realistic timelines for how long you might need to stay on the medication